RAIN News and Press, Rain Therapeutics Inc. From 11/19/21

Rain Therapeutics (NASDAQ:RAIN) announces that the first patient has been dosed in the Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of MDM2-amplified advanced solid tumors. Approx. 65 patients are anticipated to be enrolle...

NEWARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that the first patient has been dosed in the multicenter, single arm, open-label, Phase 2 baske...

Image source: The Motley Fool. Rain Therapeutics Inc. (NASDAQ: RAIN) Q3 2021 Earnings Call Nov 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Rain Therapeutics Inc. (RAIN) Q3 2021 Earnings Call Transcript

Rain Therapeutics, Inc.(RAIN) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Glenn Garmont - LifeSci Advisors, Investor Relations Avanish Vellanki - Chief Executive Officer Richard Bryce - Chief Medical Officer Robert Doebele - Chief Scientific Officer Nels...

Rain Therapeutics (NASDAQ:RAIN): Q3 GAAP EPS of -$0.70 misses by $0.19. Cash, cash equivalents and short-term investments of $150.08M Press Release For further details see: Rain Therapeutics EPS misses by $0.19

New Phase 2 clinical trial planned for milademetan in Merkel cell carcinoma (MCC), the MANTRA-3 trial, to start in mid-2022 Quarter-end cash position of $150.1 million provides runway to advance research and development (R&D) pipeline and complete all three planned clinical tr...

The Merkel cell trial will be prioritized over the previously planned Phase 2 trial in patients with intimal sarcoma, and will evaluate milademetan in patients with IO-refractory disease Rain to host first annual research and development (R&D) day at 11am...

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the third quarter that ended September 30, 2021 and highli...

NEWARK, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that it will host a virtual Research and Development (R&D) day on Tuesday, November 9, 202...

You can read the full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)